

Orhan Suleiman is the Senior Science Policy Advisor in FDA's Center for Drug Evaluation and Research (CDER), currently in the Office of New Drugs. He is involved in regulatory initiatives involving drug development, human research associated with radiolabeled drugs, radiation safety, and imaging. Previously he was with the Center for Devices and Radiological Health (CDRH), involved with a variety of radiation initiatives, and was actively involved in the implementation of the Mammography Quality Standards Act of 1992, a national program which established mandatory federal standards for imaging and radiation safety.

He received his BS and MS from the University of Florida, and his Ph.D. from the Johns Hopkins School of Hygiene and Public Health. His MS thesis was in nuclear medicine imaging, while his doctoral dissertation was on radiation doses from fluoroscopy.

He has served in many ways with the Conference of Radiation Control Program Directors (CRCPD), the American Association of Physicists in Medicine (AAPM), the Health Physics Society (HPS), Society of Nuclear Medicine (SNM), Drug Information Agency (DIA), International Electro-technical Commission (IEC), the International Atomic Energy Agency (IAEA), and the National Council on Radiation Protection (NCRP). He has published over 60 papers and book chapters, and made numerous presentations.